|
1
|
Lehmann JM, Holzmann B, Breitbart EW,
Schmiegelow P, Riethmüller G and Johnson JP: Discrimination between
benign and malignant cells of melanocytic lineage by two novel
antigens, a glycoprotein with a molecular weight of 113,000 and a
protein with a molecular weight of 76,000. Cancer Res. 47:841–845.
1987.
|
|
2
|
Lehmann JM, Riethmüller G and Johnson JP:
MUC18, a marker of tumor progression in human melanoma, shows
sequence similarity to the neural cell adhesion molecules of the
immunoglobulin superfamily. Proc Natl Acad Sci USA. 86:9891–9895.
1989. View Article : Google Scholar
|
|
3
|
Shih IM, Elder DE, Speicher D, Johnson JP
and Herlyn M: Isolation and functional characterization of the A32
melanoma-associated antigen. Cancer Res. 54:2514–2520.
1994.PubMed/NCBI
|
|
4
|
Shih IM, Elder DE, Hsu MY and Herlyn M:
Regulation of Mel-CAM/MUC18 expression on melanocytes of different
stages of tumor progression by normal keratinocytes. Am J Pathol.
145:837–845. 1994.PubMed/NCBI
|
|
5
|
Bardin N, Francès V, Lesaule G,
Horschowski N, George F and Sampol J: Identification of the S-Endo
1 endothelial-associated antigen. Biochem Biophys Res Commun.
218:210–216. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rummel MM, Sers C and Johnson JP: Phorbol
ester and cyclic AMP-mediated regulation of the melanoma-associated
cell adhesion molecule MUC18/MCAM. Cancer Res. 56:2218–2223.
1996.PubMed/NCBI
|
|
7
|
Xie S, Luca M, Huang S, et al: Expression
of MCAM/MUC18 by human melanoma cells leads to increased tumor
growth and metastasis. Cancer Res. 57:2295–2303. 1997.PubMed/NCBI
|
|
8
|
Wu GJ, Wu MW, Wang C and Liu Y: Enforced
expression of METCAM/MUC18 increases tumorigenesis of human
prostate cancer LNCaP cells in nude mice. J Urol. 185:1504–1512.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vainio O, Dunon D, Aïssi F, Dangy JP,
McNagny KM and Imhof BA: HEMCAM, an adhesion molecule expressed by
c-kit+ hemopoietic progenitors. J Cell Biol. 135:1655–1668.
1996.PubMed/NCBI
|
|
10
|
Taira E, Takaha N, Taniura H, Kim CH and
Miki N: Molecular cloning and functional expression of gicerin, a
novel cell adhesion molecule that binds to neurite outgrowth
factor. Neuron. 12:861–872. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aldovini D, Demichelis F, Doglioni C, et
al: M-CAM expression as marker of poor prognosis in epithelial
ovarian cancer. Int J Cancer. 119:1920–1926. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Feng G, Fang F, Liu C, Zhang F, Huang H
and Pu C: CD146 gene expression in clear cell renal cell carcinoma:
a potential marker for prediction of early recurrence after
nephrectomy. Int Urol Nephrol. 44:1663–1669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu WF, Ji SR, Sun JJ, et al: CD146
Expression Correlates with Epithelial-Mesenchymal Transition
Markers and a Poor Prognosis in Gastric Cancer. Int J Mol Sci.
13:6399–6406. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zeng Q, Li W, Lu D, et al: CD146, an
epithelial-mesenchymal transition inducer, is associated with
triple-negative breast cancer. Proc Natl Acad Sci USA.
109:1127–1132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ouhtit A, Gaur RL, Abd Elmageed ZY, et al:
Towards understanding the mode of action of the multifaceted cell
adhesion receptor CD146. Biochim Biophys Acta. 1795:130–136.
2009.PubMed/NCBI
|
|
16
|
Bu P, Gao L, Zhuang J, Feng J, Yang D and
Yan X: Anti-CD146 monoclonal antibody AA98 inhibits angiogenesis
via suppression of nuclear factor-kappaB activation. Mol Cancer
Ther. 5:2872–2878. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wellbrock J and Fiedler W: CD146: a new
partner for VEGFR2. Blood. 120:2164–2165. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Johnson JP, Rothbächer U and Sers C: The
progression associated antigen MUC18: a unique member of the
immunoglobulin supergene family. Melanoma Res. 3:337–340. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Zheng C, Zhang J, et al:
Generation and characterization of a panel of monoclonal antibodies
against distinct epitopes of human CD146. Hybridoma (Larchmt).
27:345–352. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mathew A and George PS: Trends in
incidence and mortality rates of squamous cell carcinoma and
adenocarcinoma of cervix - worldwide. Asian Pac J Cancer Prev.
10:645–650. 2009.PubMed/NCBI
|
|
21
|
Prat J: Prognostic parameters of
endometrial carcinoma. Hum Pathol. 35:649–662. 2004. View Article : Google Scholar
|
|
22
|
Kang Y, Wang F, Feng J, et al: Knockdown
of CD146 reduces the migration and proliferation of human
endothelial cells. Cell Res. 16:313–318. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zheng C, Qiu Y, Zeng Q, et al: Endothelial
CD146 is required for in vitro tumor-induced angiogenesis: the role
of a disulfide bond in signaling and dimerization. Int J Biochem
Cell Biol. 41:2163–2172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
25
|
Nolen BM and Lokshin AE: Protein
biomarkers of ovarian cancer: the forest and the trees. Future
Oncol. 8:55–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tanyi JL and Scholler N: Oncology
biomarkers for gynecologic malignancies. Front Biosci (Elite Ed).
4:1097–1110. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chmura A, Wojcieszek A, Mrochem J, et al:
Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the
diagnosis and monitoring of cervical squamous cell carcinoma.
Ginekol Pol. 80:361–366. 2009.(In Polish).
|
|
28
|
Micke O, Bruns F, Schäfer U, Prott FJ and
Willich N: The impact of squamous cell carcinoma (SCC) antigen in
patients with advanced cancer of uterine cervix treated with
(chemo-)radiotherapy. Anticancer Res. 25:1663–1666. 2005.PubMed/NCBI
|
|
29
|
Jankovic MM and Milutinovic BS: Glycoforms
of CA125 antigen as a possible cancer marker. Cancer Biomark.
4:35–42. 2008.PubMed/NCBI
|
